18.7% reported weight loss · 2% loss with placebo · 24 weeks
6 mg once weekly
Chinese adults with overweight or obesity without diabetes
Protocol efficacy estimand regardless of dose modification. United Biotechnology retains China rights; Novo ex-China license; global phase 1b/2a ongoing and China phase 3 planned.
Safety context
Most reported adverse events were mild or moderate gastrointestinal events.
Limitations: Highest dose 6 mg selected. Headline 19.7% arose in 4 mg arm starting 1 mg; conference/sponsor results.
No approved trade name verified as of September 13, 2026; the compound name and development codes are not trade names.
United Biotechnology (Hengqin) / The United Laboratories · Originator; retains development and commercialization rights in Mainland China, Hong Kong, Macau and Taiwan.; Novo Nordisk · Exclusive worldwide development, manufacturing and commercialization licensee outside those retained territories.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Activates GLP-1, GIP and glucagon receptors.
Structure not yet verified
Structure not verified
Activates GLP-1, GIP and glucagon receptors.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
New liver-development plans target MASH and alcohol-related disease
Novo plans a Phase 3 MASH program for UBT251 and a dedicated efruxifermin alcohol-related liver disease trial during 2027. Plans do not establish initiation or clinical benefit in the new indications. Historical efruxifermin biopsy data displayed in the presentation are not new September results.